All In Biotech

Drug Trial Radar · NCT02873936

Filgotinib Versus Placebo in Adults With Active Rheumatoid Arthritis (RA) Who Have an Inadequate Response to Biologic Disease-modifying Anti-rheumatic Drug(s) (DMARDs) Treatment

A Randomized, Double-blind, Placebo-controlled, Multicenter, Phase 3 Study to Assess the Efficacy and Safety of Filgotinib Administered for 24 Weeks in Combination With Conventional Synthetic Disease-modifying Anti-rheumatic Drug(s) (csDMARDs) to Subjects With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Biologic DMARD(s) Treatment

Last checked: Nov 20, 2026Latest source record: May 13, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 449 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

449

Actual

Start

Jul 27, 2016

Primary completion

Mar 20, 2018

Study completion Jun 26, 2018

Sponsor

Lead sponsor
Gilead SciencesGilead Sciences (GILD)
Sponsor type
Industry
Collaborators
Lakefront Biotherapeutics NV
First posted
Aug 22, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective of this study is to evaluate the effects of filgotinib versus placebo for the treatment of signs and symptoms of rheumatoid arthritis (RA) as measured by the percentage of participants achieving an American College of Rheumatology 20% improvement response (ACR20) at Week 12.

Conditions

  • Rheumatoid Arthritis

Interventions

  • FilgotinibDrug

    Tablet(s) administered orally once daily

  • Placebo to match filgotinibDrug

    Tablet(s) administered orally once daily

  • csDMARDsDrug

    csDMARDs may include one or two of the following: methotrexate (MTX), hydroxychloroquine or chloroquine, sulfasalazine, and/or leflunomide (combination of leflunomide and MTX is not allowed)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants Who Achieved an American College of Rheumatology (ACR) 20% Improvement (ACR20) Response at Week 12Time frame: Week 12

Locations

104 sites in 15 countries. Site status is shown where the registry gives one.

  • Site not named

    Huntsville, Alabama

  • Site not named

    Gilbert, Arizona

  • Site not named

    Covina, California

  • Site not named

    Hemet, California

  • Site not named

    La Jolla, California

  • Site not named

    Palm Desert, California

  • Site not named

    Palo Alto, California

  • Site not named

    Riverside, California

  • Site not named

    Upland, California

  • Site not named

    Victorville, California

  • Site not named

    Whittier, California

  • Site not named

    Aventura, Florida

  • Site not named

    DeBary, Florida

  • Site not named

    Jacksonville, Florida

  • Site not named

    Miami, Florida

  • Site not named

    Orlando, Florida

  • Site not named

    Plantation, Florida

  • Site not named

    Port Richey, Florida

  • Site not named

    Decatur, Georgia

  • Site not named

    Kansas City, Kansas

  • Site not named

    Wichita, Kansas

  • Site not named

    Elizabethtown, Kentucky

  • Site not named

    Lexington, Kentucky

  • Site not named

    Cumberland, Maryland

  • Site not named

    Frederick, Maryland

  • Site not named

    Worcester, Massachusetts

  • Site not named

    Detroit, Michigan

  • Site not named

    Saint Clair Shores, Michigan

  • Site not named

    Hattiesburg, Mississippi

  • Site not named

    Tupelo, Mississippi

  • Site not named

    St Louis, Missouri

  • Site not named

    Lincoln, Nebraska

  • Site not named

    Lebanon, New Hampshire

  • Site not named

    Freehold, New Jersey

  • Site not named

    Toms River, New Jersey

  • Site not named

    Brooklyn, New York

  • Site not named

    Charlotte, North Carolina

  • Site not named

    Greenville, North Carolina

  • Site not named

    Salisbury, North Carolina

  • Site not named

    Middleburg Heights, Ohio

Showing 40 of 104 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.